PODD Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of 12.4% compared to Insulet Corp.'s net margin of 12.68%. Insulet Corp.'s return on equity of 18.92% beat Boston Scientific Corp.'s return on equity of 12.46%.

Insulet Corp. has a consensus price target of $369.64, signalling upside risk potential of 47.36%. On the other hand Boston Scientific Corp. has an analysts' consensus of $106.78 which suggests that it could grow by 45.34%. Given that Insulet Corp. has higher upside potential than Boston Scientific Corp., analysts believe Insulet Corp. is more attractive than Boston Scientific Corp..

Insulet Corp. has a beta of 1.412, which suggesting that the stock is 41.175% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.441%.

Insulet Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet Corp. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

Insulet Corp. quarterly revenues are $706.3M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. Insulet Corp.'s net income of $87.6M is lower than Boston Scientific Corp.'s net income of $670M. Notably, Insulet Corp.'s price-to-earnings ratio is 72.78x while Boston Scientific Corp.'s PE ratio is 37.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet Corp. is 7.20x versus 5.47x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical, Inc. has a net margin of 12.4% compared to Insulet Corp.'s net margin of 15.47%. Insulet Corp.'s return on equity of 18.92% beat Globus Medical, Inc.'s return on equity of 10.08%.

Insulet Corp. has a consensus price target of $369.64, signalling upside risk potential of 47.36%. On the other hand Globus Medical, Inc. has an analysts' consensus of $107.17 which suggests that it could grow by 21.42%. Given that Insulet Corp. has higher upside potential than Globus Medical, Inc., analysts believe Insulet Corp. is more attractive than Globus Medical, Inc..

Insulet Corp. has a beta of 1.412, which suggesting that the stock is 41.175% more volatile than S&P 500. In comparison Globus Medical, Inc. has a beta of 1.056, suggesting its more volatile than the S&P 500 by 5.621%.

Insulet Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet Corp. pays -- of its earnings as a dividend. Globus Medical, Inc. pays out -- of its earnings as a dividend.

Insulet Corp. quarterly revenues are $706.3M, which are smaller than Globus Medical, Inc. quarterly revenues of $769M. Insulet Corp.'s net income of $87.6M is lower than Globus Medical, Inc.'s net income of $119M. Notably, Insulet Corp.'s price-to-earnings ratio is 72.78x while Globus Medical, Inc.'s PE ratio is 28.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet Corp. is 7.20x versus 4.39x for Globus Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of 12.4% compared to Insulet Corp.'s net margin of 27.89%. Insulet Corp.'s return on equity of 18.92% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.

Insulet Corp. has a consensus price target of $369.64, signalling upside risk potential of 47.36%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $611.82 which suggests that it could grow by 23.32%. Given that Insulet Corp. has higher upside potential than Intuitive Surgical, Inc., analysts believe Insulet Corp. is more attractive than Intuitive Surgical, Inc..

Insulet Corp. has a beta of 1.412, which suggesting that the stock is 41.175% more volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.653, suggesting its more volatile than the S&P 500 by 65.303%.

Insulet Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet Corp. pays -- of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend.

Insulet Corp. quarterly revenues are $706.3M, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.9B. Insulet Corp.'s net income of $87.6M is lower than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, Insulet Corp.'s price-to-earnings ratio is 72.78x while Intuitive Surgical, Inc.'s PE ratio is 62.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet Corp. is 7.20x versus 17.88x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Stryker Corp. has a net margin of 12.4% compared to Insulet Corp.'s net margin of 11.84%. Insulet Corp.'s return on equity of 18.92% beat Stryker Corp.'s return on equity of 15.17%.

Insulet Corp. has a consensus price target of $369.64, signalling upside risk potential of 47.36%. On the other hand Stryker Corp. has an analysts' consensus of $424.40 which suggests that it could grow by 16.69%. Given that Insulet Corp. has higher upside potential than Stryker Corp., analysts believe Insulet Corp. is more attractive than Stryker Corp..

Insulet Corp. has a beta of 1.412, which suggesting that the stock is 41.175% more volatile than S&P 500. In comparison Stryker Corp. has a beta of 0.873, suggesting its less volatile than the S&P 500 by 12.679%.

Insulet Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker Corp. offers a yield of 0.94% to investors and pays a quarterly dividend of $0.88 per share. Insulet Corp. pays -- of its earnings as a dividend. Stryker Corp. pays out 40.48% of its earnings as a dividend. Stryker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Insulet Corp. quarterly revenues are $706.3M, which are smaller than Stryker Corp. quarterly revenues of $7.2B. Insulet Corp.'s net income of $87.6M is lower than Stryker Corp.'s net income of $849M. Notably, Insulet Corp.'s price-to-earnings ratio is 72.78x while Stryker Corp.'s PE ratio is 43.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet Corp. is 7.20x versus 5.60x for Stryker Corp.. Usually stocks with elevated PS ratios are considered overvalued.